IP Library Granted Patent US 7,429,486
Granted Patent B2
US 7,429,486 · App. 11/593,279 · Granted Sep 30, 2008

Recombinant production of mixtures of antibodies

Assignee: Crucell Holland B.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,429,486
App. No.
11/593,279
Granted
Sep 30, 2008
Kind
B2
Abstract

The invention provides methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.

Claims (20)

1. An isolated host cell capable of producing three or more non-identical antibodies, said host cell comprising: at least one exogenously introduced nucleic acid sequence encoding an immunoglobulin light chain and exogenously introduced nucleic acid sequences encoding at least three different immunoglobulin heavy chains, wherein said at least three different immunoglobulin heavy chains are capable of pairing with said immunoglobulin light chain to form the three or more non-identical antibodies that bind antigen.

2. The host cell of claim 1 , wherein said at least one exogenously introduced nucleic acid sequence encoding the immunoglobulin light chain is integrated into the host cell's genome.

3. The host cell of claim 1 , wherein said host cell is identified using high throughput procedures.

4. The host cell of claim 1 , wherein said at least one exogenously introduced nucleic acid sequence is present on a low copy number vector and said host cell produces 1 to 20 picograms per cell per day of two or more non-identical antibodies.

5. The host cell of claim 1 , wherein one immunoglobulin light chain is introduced into the host cell.

6. The host cell of claim 1 , wherein said host cell comprises a human embryonic retina cell, and wherein said host cell has been immortalized or transformed by adenoviral E1 nucleic acid sequences.

7. The host cell of claim 1 , wherein said host cell is obtained from a cell as deposited under ECACC number 96022940.

8. The host cell of claim 1 , wherein the three or more non-identical antibodies comprise two or more non-identical antibodies that are of different isotypes.

9. The host cell of claim 8 , wherein said different isotypes comprise at least an IgG and an IgA.

10. The host cell of claim 8 , wherein said different isotypes comprise at least an IgG1 and an IgG3 antibody.

11. The host cell of claim 1 , wherein said three or more non-identical antibodies are of an isotype independently selected from the group consisting of: IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE and IgM.

12. The host cell of claim 1 , wherein said three or more non-identical antibodies comprise at least one bispecific antibody.

13. The host cell of claim 1 , wherein said host cell is present in a non-human animal.

14. The host cell of claim 13 , wherein said exogenously introduced nucleic acid sequences encoding the immunoglobulin light and at least three different immunoglobulin heavy chains comprise a tissue-specific promoter.

15. The host cell of claim 1 , wherein said exogenously introduced nucleic acid sequences encoding at least three different immunoglobulin heavy chains are integrated into the host cell's genome.

16. The host cell of claim 1 , wherein at least two of said three or more non-identical antibodies bind to different epitopes of at least one target antigen.

17. The host cell of claim 1 , wherein said at least three different immunoglobulin heavy chains have identical constant regions.

18. The host cell of claim 1 , wherein at least two of said three or more non-identical antibodies bind to different antigens.

19. A culture of host cells producing three or more non-identical antibodies from a single cell within the culture, said culture comprising an isolated host cell according to claim 1 and a culture medium.

20. The culture according to claim 1 , wherein said culture produces said three or more non-identical antibodies from a single cell within the culture for more than 20 population doublings.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 041675 FRAME: 0842. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE ADDRESS. Recorded Apr 4, 2017
From: MERUS N.V.
To: MERUS N.V.
Reel/Frame 042322/0304 →
CHANGE OF ADDRESS Recorded Feb 10, 2017
From: MERUS N.V.
To: MERUS N.V.
Reel/Frame 041675/0842 →
CHANGE OF NAME Recorded Jun 1, 2016
From: MERUS B.V.
To: MERUS N.V.
Reel/Frame 038853/0599 →
DEED OF TRANSFER Recorded Jun 26, 2009
From: CRUCELL HOLLAND B.V.
To: MERUS B.V.
Reel/Frame 022878/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2006
From: VAN BERKEL, PATRICK H.C.; BRUS, RONALD H.P.; LOGTENBERG, TON; BOUT, ABRAHAM
To: CRUCELL HOLLAND B.V.
Reel/Frame 018570/0161 →
Priority Claims (2)
EP 02077953 · Jul 18, 2002 · regional
WO PCT/EP03/50201 · May 27, 2003 · international
Continuity (4)
Division 1103976700 · Jan 18, 2005
Continuation PCTEP030769000 · Jul 15, 2003
Provisional Application 6039706600 · Jul 18, 2002
Related Publication 20070077624A1 · Apr 5, 2007